Takeda's Investments In Data Science Seek Improved Trial Outcomes, R&D Efficiency
Executive Summary
President of R&D Andrew Plump notes that much of the work to rationalize Takeda's pipeline after its Shire acquisition took place years ago when the Japanese pharma streamlined its R&D organization, but investments in data science to improve clinical trial outcomes and R&D efficiency are ongoing.
You may also be interested in...
Real-World Reluctance? Despite Guidance, Drug Developers Wary Of RWE-Based Trials
Biopharma companies are reluctant to rely on real-world evidence trials, but while uncertainty remains about how these novel studies will be accepted, US and other regulators are encouraging drug developers to take a chance – and some have taken on the challenge.
Takeda's Latest Investment Reflects Long-Term Shift In R&D Strategy
The Japanese pharma's new San Diego site brings together scientists from multiple locations to identify and validate therapeutic candidates across multiple modalities to enhance Takeda's global internal and external programs.
Real-World Evidence: US FDA Framework Emphasizes Data Fitness And Study Quality
Agency’s approach to assessing real-world evidence for effectiveness will be guided by three key principles: fitness for use of the underlying data, adequacy of the study design, and satisfactory monitoring and data collection.